Top Page
Sanofi
(NASDAQ:SNY)
Sanofi (SNY) vs. SPDR S&P 500 ETF (SPY)
Sanofi Business Overview & Revenue Model
Sanofi Earnings Call Summary
Sanofi Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 43.13B | 44.29B | 41.62B | 40.56B | 39.17B | 37.37B |
| Gross Profit | 30.89B | 31.08B | 28.99B | 28.68B | 26.92B | 25.21B |
| EBITDA | 9.47B | 11.03B | 11.39B | 13.51B | 11.54B | 17.88B |
| Net Income | 9.13B | 5.56B | 5.40B | 8.37B | 6.22B | 12.29B |
Balance Sheet | ||||||
| Total Assets | 124.96B | 132.80B | 126.46B | 126.72B | 120.24B | 114.41B |
| Cash, Cash Equivalents and Short-Term Investments | 15.36B | 7.93B | 8.71B | 12.74B | 10.10B | 13.91B |
| Total Debt | 22.29B | 17.91B | 18.70B | 21.21B | 22.41B | 23.68B |
| Total Liabilities | 54.68B | 54.94B | 52.11B | 51.57B | 51.21B | 51.16B |
| Stockholders Equity | 70.01B | 77.51B | 74.04B | 74.78B | 68.68B | 63.11B |
Cash Flow | ||||||
| Free Cash Flow | 2.09B | 5.89B | 8.64B | 8.32B | 8.48B | 5.33B |
| Operating Cash Flow | 2.09B | 9.08B | 10.26B | 10.53B | 10.52B | 7.45B |
| Investing Cash Flow | -776.00M | -4.41B | -6.20B | -2.08B | -7.30B | 3.59B |
| Financing Cash Flow | -592.00M | -5.76B | -8.05B | -5.82B | -7.06B | -6.49B |
Sanofi Technical Analysis
Sanofi Risk Analysis
Sanofi Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $270.12B | 14.40 | 39.51% | 3.12% | 1.59% | 58.02% | |
80 Outperform | $274.10B | 19.55 | 32.93% | 2.87% | 11.53% | -15.21% | |
78 Outperform | $154.97B | 19.35 | 40.53% | 2.52% | 2.76% | 6407.19% | |
75 Outperform | $113.56B | 11.58 | 8.39% | 4.58% | -9.32% | 120.62% | |
74 Outperform | $145.84B | 14.95 | 10.59% | 6.65% | 4.44% | 128.96% | |
73 Outperform | $112.50B | 18.66 | 33.84% | 4.84% | 1.26% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Sanofi Corporate Events
On January 5, 2026, Sanofi announced that the US Food and Drug Administration has accepted for priority review a supplemental biologics license application for its type 1 diabetes drug Tzield (teplizumab-mzwv), seeking to extend its use from patients aged eight and older to children as young as one year with stage 2 type 1 diabetes, with a target decision date of April 29, 2026. The filing, based on interim one-year data from the ongoing PETITE-T1D phase 4 study in children under eight, underscores Tzield’s role as the first and only disease-modifying therapy for autoimmune type 1 diabetes and, if approved, would significantly strengthen Sanofi’s position in diabetes immunotherapy by opening access to a younger pediatric population and potentially reshaping early-stage disease management for patients and caregivers globally.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On December 24, 2025, Sanofi announced an agreement to acquire Dynavax Technologies Corporation, a commercial-stage vaccines company, in a cash transaction valuing Dynavax’s equity at about $2.2 billion, as it looks to strengthen its position in adult immunization. The deal will add Dynavax’s marketed adult hepatitis B vaccine HEPLISAV-B, noted for its faster two-dose, one-month regimen, and a phase 1/2 shingles vaccine candidate Z-1018, along with additional vaccine pipeline projects; the Dynavax board unanimously approved the transaction, which Sanofi will fund with cash and which is expected to close in the first quarter of 2026, subject to customary regulatory and tender offer conditions, with no impact anticipated on Sanofi’s 2025 financial guidance and potential long-term benefits for its vaccines franchise and adult vaccination market reach.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On December 24, 2025, Sanofi announced that the US Food and Drug Administration issued a complete response letter for its new drug application for tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis in adults, marking a sharp reversal from prior regulatory interactions that had led to breakthrough therapy designation for the candidate. The company expressed disappointment with the FDA’s decision but said it remains committed to working with the agency to find a path forward, while highlighting that tolebrutinib already holds a provisional approval in the United Arab Emirates and is under review in the European Union and other markets; Sanofi is also conducting an IFRS impairment test on the intangible asset value of tolebrutinib, with results due alongside its fourth-quarter and full-year 2025 earnings, although it expects no impact on business net income, earnings per share, or its 2025 financial guidance.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On December 23, 2025, the European Commission approved Sanofi’s Wayrilz (rilzabrutinib) as the first Bruton’s tyrosine kinase (BTK) inhibitor indicated for adult immune thrombocytopenia (ITP) patients who are refractory to other treatments, marking a significant expansion of Sanofi’s rare disease portfolio in a complex, underserved segment. The once-daily oral therapy, already approved in the US and UAE and supported by positive phase 3 LUNA 3 data showing rapid, durable platelet responses and quality-of-life improvements versus placebo, strengthens Sanofi’s positioning in immunology and rare diseases and underscores the strategic value of its BTK and TAILORED COVALENCY® platform, with additional rare indications under investigation that could further broaden its specialty care franchise.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On December 17, 2025, Sanofi announced that the European Medicines Agency granted orphan designation to efdoralprin alfa (SAR447537), its investigational recombinant human alpha-1 antitrypsin-Fc fusion protein, for the potential treatment of alpha-1 antitrypsin deficiency (AATD) related emphysema, a rare and debilitating respiratory disease. The candidate recently showed superiority to a plasma-derived standard-of-care therapy in a global Phase 2 head-to-head trial, meeting all primary and key secondary endpoints with dosing every three or four weeks, adding to prior U.S. fast track and orphan drug designations and reinforcing Sanofi’s strategy of building a differentiated rare-disease portfolio in an indication where no new therapies have been introduced since 1987 and where underdiagnosis remains high.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On December 19, 2025, Sanofi announced it had reached a voluntary agreement with the Trump Administration to cut US medicine costs while reinforcing the country’s role in biopharmaceutical innovation and manufacturing. The three-year framework gives Sanofi a Section 232 tariff exemption on its US imports and commits the company to align Medicaid prices for several wholly owned medicines with those in other high‑income countries, implying average price reductions of around 61% for certain diabetes, cardiovascular, neurological and oncology treatments, and to offer US patients direct access to selected drugs, including insulins, at discounts nearing 70% via TrumpRx.gov and other direct‑to‑patient platforms. Sanofi will also pursue a more ‘balanced’ pricing strategy in other wealthy markets and build on a previously announced US$20 billion investment plan to upgrade and expand manufacturing capacity, with management stressing that the accord supports its Take the Lead growth strategy and does not alter its financial outlook over the agreement period, signaling a bid to protect long-term innovation and US industrial presence while responding to political and public pressure on drug prices.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Sanofi announced on December 15, 2025, that the U.S. regulatory review process for tolebrutinib, a treatment for non-relapsing secondary progressive multiple sclerosis (nrSPMS), is expected to extend beyond the initial target action date of December 28, 2025. The company is in ongoing discussions with the FDA and anticipates further guidance by the end of the first quarter of 2026. Sanofi has submitted an expanded access protocol for tolebrutinib, emphasizing its commitment to providing access to this investigational therapy, which targets smoldering neuroinflammation, a key driver of disability progression in multiple sclerosis.
The most recent analyst rating on (SNY) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
In December 2025, Sanofi announced the completion of its acquisition of Vicebio Ltd, which enhances its capabilities in vaccine design and development. This acquisition introduces an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), expanding Sanofi’s respiratory vaccine portfolio with a non-mRNA option. Additionally, Sanofi received approval in China for its drugs Qfitlia and Cablivi, which are intended to expand care for rare diseases, marking a significant step in broadening its market reach and strengthening its position in the global pharmaceutical industry.
The most recent analyst rating on (SNY) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On November 25, 2025, Sanofi and Regeneron announced that the European Commission approved Dupixent (dupilumab) as the first targeted medicine in over a decade for treating moderate-to-severe chronic spontaneous urticaria (CSU) in the EU. This approval, based on phase 3 studies, marks a significant advancement for patients with CSU, providing a new treatment option that significantly reduces symptoms like itch and hives, which were previously inadequately controlled by standard antihistamines. The approval is expected to enhance Sanofi’s position in the immunology market and offer a new therapeutic option for the estimated 270,000 individuals in the EU suffering from CSU.
The most recent analyst rating on (SNY) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
In November 2025, Sanofi announced significant advancements in its pharmaceutical offerings. On November 7, 2025, Sanofi, in collaboration with Regeneron, revealed that their drug Dupixent met all primary and secondary endpoints in a pivotal phase 3 study for allergic fungal rhinosinusitis (AFRS), leading to the acceptance of a supplemental biologics license application for FDA priority review. This marks a potential new indication for Dupixent, which could become the first treatment specifically approved for AFRS. Additionally, on November 14, 2025, Sanofi’s drug Teizeild received a recommendation for EU approval for patients with stage 2 type 1 diabetes. These developments highlight Sanofi’s ongoing commitment to expanding its treatment portfolio and enhancing its market position in the pharmaceutical industry.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On November 3, 2025, Sanofi announced the issuance of $3 billion in notes, including floating and fixed rate notes due in 2027, 2028, and 2032. This strategic financial move is expected to enhance Sanofi’s capital structure and support its long-term growth objectives, potentially impacting its market position and providing liquidity for future investments.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On October 22, 2025, Sanofi announced that its investigational drug, efdoralprin alfa, met all primary and key secondary endpoints in a phase 2 study for alpha-1 antitrypsin deficiency (AATD) emphysema. The drug showed superiority over standard plasma-derived therapy, offering less frequent dosing and maintaining higher functional AAT levels, which could significantly improve treatment convenience for patients. These results highlight the potential of efdoralprin alfa as a restorative recombinant therapy, reinforcing Sanofi’s commitment to addressing unmet medical needs in rare and respiratory conditions. The study’s positive outcomes may enhance Sanofi’s industry positioning and offer new hope to stakeholders in the AATD community.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On October 28, 2025, Sanofi announced the successful pricing of a $3 billion bond issue across five tranches, with proceeds intended for general corporate purposes. This strategic financial move, coordinated by major financial institutions, is expected to support Sanofi’s operational capabilities and strengthen its position in the biopharmaceutical industry.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Sanofi has released its condensed half-year consolidated financial statements for the six months ending June 30, 2025, along with information on its financial results for the first half and third quarter of 2025. The report highlights a decrease in total assets from December 2024 to June 2025, indicating potential challenges in asset management or strategic adjustments. This financial disclosure provides stakeholders with insights into Sanofi’s financial health and operational performance during the first half of the year.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
In its Q3 2025 report, Sanofi announced a 7.0% increase in sales at constant exchange rates, driven by strong performances from new pharma launches and Dupixent, despite a decline in vaccine sales. The company achieved significant milestones, including regulatory approvals for Wayrilz and Tzield, and completed the acquisition of Vigil Neuroscience. Sanofi’s strategic focus on science and patient-centric solutions contributed to its continued growth, with plans to complete a €5 billion share buyback by the end of 2025, reinforcing its commitment to delivering shareholder value.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
In October 2025, Sanofi faced a setback when the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the marketing authorization application for Rezurock, a treatment for chronic graft-versus-host disease. Despite this, Sanofi remains committed to pursuing approval, citing strong clinical and real-world evidence supporting Rezurock’s efficacy and safety. Additionally, Sanofi’s Wayrilz received a positive recommendation for EU approval to treat immune thrombocytopenia, and their high-dose influenza vaccine showed superior protection for older adults. Sanofi’s Tzield was also accepted for expedited review in the US for stage 3 type 1 diabetes, highlighting the company’s ongoing efforts to expand its therapeutic offerings.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
On October 8, 2025, Sanofi announced that its investigational therapy AlphaMedixTM (212Pb-DOTAMTATE) met all primary efficacy endpoints in a phase 2 study for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study showed clinically meaningful benefits in both PRRT-naïve and PRRT-exposed patients, with a manageable safety profile. These results highlight the potential of Targeted Alpha Therapy with lead-212 as a new treatment option, reinforcing Sanofi’s commitment to innovative cancer therapies. The findings will be discussed with health authorities and presented at the 2025 European Society for Medical Oncology Congress.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.